Combination pharmacotherapy in unipolar depression

References

• WHO. The World Health Report 2001. Mental health: new understanding, new hope. WHO, Geneva, Switzerland (2001).
   Google Scholar
• Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder. Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatry62, 1097–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull. World Health Organ.82, 858–866 (2004).
   PubMed Web of Science ®Google Scholar
• Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch. Gen. Psychiatry61, 1097–1103 (2004).
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry62(Suppl. 16), 10–17 (2001).
   PubMedGoogle Scholar
• Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect Disord.89, 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry163, 232–239 (2006).
   PubMed Web of Science ®Google Scholar
• Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J. Psychopharmacol.20(Suppl. 3), 19–28 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry62(Suppl. 18), 4–11 (2001).
   PubMed Web of Science ®Google Scholar
• Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed out-patients. Br. Med. J.2, 1315–1317 (1979).
   PubMed Web of Science ®Google Scholar
• Razani J, White KL, White J et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch. Gen. Psychiatry40, 657–661 (1983).
   PubMed Web of Science ®Google Scholar
• O’Brien S, McKeon P, O’Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br. J. Psychiatry162, 363–368 (1993).
   PubMed Web of Science ®Google Scholar
• Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch. Gen. Psychiatry35, 639–642 (1978).
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am. J. Psychiatry151, 1372–1374 (1994).
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg A et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J. Clin. Psychopharmacol.22, 379–387 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiatry55, 296–300 (2004).
   PubMed Web of Science ®Google Scholar
• Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol.19, 177–182 (1999).
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne FL, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression nonresponders to fluoxetine alone. Acta Psychiatr. Scand.103, 66–72 (2001).
   PubMed Web of Science ®Google Scholar
• Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the cute treatment of major depression. Pharmacopsychiatry31, 48–54 (1998).
   PubMed Web of Science ®Google Scholar
• Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomized study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology161, 143–151 (2002).
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry51, 183–188 (2002).
   PubMed Web of Science ®Google Scholar
• Souery D, Amsterdam J, de Montigny C et al. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol.9, 83–91 (1999).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163, 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME. Effectiveness of antidepressants: comparative remission rates. J. Clin. Psychiatry64(Suppl. 2), 3–7 (2003).
   Google Scholar
• The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet361, 799–808 (2003).
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Nonresponse to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology128, 421–425 (1996).
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, García-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress. Anxiety5, 84–90 (1997).
   PubMedGoogle Scholar
• Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J. Affect Disord.34, 187–192 (1995).
   PubMed Web of Science ®Google Scholar
• König F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry30, 93–96 (1997).
   PubMed Web of Science ®Google Scholar
• Hawley CJ, Quick SJ, Ratnam S, Pattinson HA, McPhee S. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. Int. Clin. Psychopharmacol.11, 187–191 (1996).
   PubMed Web of Science ®Google Scholar
• Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J. Clin. Psychiatry55, 24–25 (1994).
   PubMed Web of Science ®Google Scholar
• Levitt AJ, Joffe RT, Kamil R, McIntyre R. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J. Clin. Psychiatry60, 613–616 (1999).
   PubMed Web of Science ®Google Scholar
• Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J. Clin. Psychiatry56, 338–343 (1995).
   PubMed Web of Science ®Google Scholar
• Spier SA. Use of bupropion with SRIs and venlafaxine. Depress. Anxiety7, 73–75 (1998).
   PubMedGoogle Scholar
• Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry63, 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J. Clin. Psychopharmacol.23, 27–30 (2003).
   PubMed Web of Science ®Google Scholar
• Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry65, 337–340 (2004).
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J. Clin. Psychiatry60, 45–49 (1999)
   PubMed Web of Science ®Google Scholar
• Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. Hum. Psychopharmacol.15, 143–145 (2000).
   PubMed Web of Science ®Google Scholar
• Hawley CJ, Sivakumaaran T, Ochocki M, Bevan J. Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression. 13th Congress of the European College of Neuropsychopharmacology, Munich, Germany S184 (2000).
   Google Scholar
• Rubio G, San L, López-Muñoz F, García-García P, Álamo C. Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors. Actas Esp. Psiquiatr.31, 315–324 (2003).
   PubMed Web of Science ®Google Scholar
• Rubio G, San L, López-Muñoz F, Alamo C. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J. Affect Disord.81, 67–72 (2004).
   PubMed Web of Science ®Google Scholar
• Tiller JWG, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy. Aust. NZJ Psychiatry26, 327–329 (1992).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry65, 62–67 (2004).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J. Clin. Psychiatry66, 844–848 (2005).
   PubMed Web of Science ®Google Scholar
• Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J. Biol. Psychiatry3, 167 (2002).
   Google Scholar
• Robertson MM, Trimble MR. Major tranquilizers used as antidepressants: a review. J. Affect Disord.4, 173–193 (1982).
   PubMed Web of Science ®Google Scholar
• Ellis PM, Hickie IB, Smith DA. RANZCP Clinical Practice Guidelines. Summary of guideline for the treatment of depression. Australas Psychiatry11, 34–38 (2003).
   Google Scholar
• Kennedy S, Lam R, Cohen N, Ravindran A. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry.46(Suppl. 1), S38–S58 (2001).
   PubMedGoogle Scholar
• National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. National Institute for Clinical Excellence, London, UK (2004).
   Google Scholar
• Schatzberg AF. New approaches to managing psychotic depression. J. Clin. Psychiatry64(Suppl. 1), 19–23 (2003).
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J. Clin. Psychiatry60, 116–118 (1999).
   PubMed Web of Science ®Google Scholar
• Matthews JD, Bottonari KA, Polania LM et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psychiatry63, 1164–1170 (2002).
   PubMed Web of Science ®Google Scholar
• Anton RF, Burch EA. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am. J. Psychiatry147, 1203–1208 (1990).
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Sweet RA, Rosen J et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J. Clin. Psychiatry62, 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Spiker DG, Cofsky Weiss J, Dealy RS et al. The pharmacological treatment of delusional depression. Am. J. Psychiatry142, 430–436 (1985).
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF et al. Double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol.24, 365–373 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry66(Suppl. 8), 13–21 (2005).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J. Clin. Psychiatry65, 975–981 (2004).
   PubMed Web of Science ®Google Scholar
• Dubé S, Andersen SW, Paul SA et al. Meta-analysis of olanzapine-fluoxetine use in treatment-resistant depression [abstract]. Eur. Neuropsychopharmacol.12(Suppl. 3), S180 (2002).
   Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry158, 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry66, 1289–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Benazzi F. Fluoxetine and olanzapine for resistant depression. Am. J. Psychiatry159, 155–156 (2002).
   PubMedGoogle Scholar
• Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry64, 1349–1356 (2003).
   PubMed Web of Science ®Google Scholar
• Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am. J. Psychiatry162, 796–798 (2005).
   PubMed Web of Science ®Google Scholar
• Devarajan S, Dursun SM. Olanzapine plus venlafaxine in treatment-resistant depression. J. Psychopharmacol.19, 434–435 (2005).
   PubMed Web of Science ®Google Scholar
• Caetano D, Caetano SC. Olanzapine in the treatment of resistant depression. Aust. NZJ Psychiatry39, 108–109 (2005).
   PubMedGoogle Scholar
• Wang TS, Chou YH, Shiah IS. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry30, 306–309 (2006).
   Google Scholar
• O’Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J. Clin. Psychopharmacol.18, 89–91 (1998).
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry60, 256–259 (1999).
   PubMed Web of Science ®Google Scholar
• Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin. Psychiatry63, 733–736 (2002).
   PubMed Web of Science ®Google Scholar
• Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J. Clin. Psychopharmacol.20, 495–496 (2000).
   PubMed Web of Science ®Google Scholar
• Viner MW, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J. Clin. Psychopharmacol.23, 104–106 (2003).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry65, 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Simon JS, Nemeroff CB. Aripiprazole augmentation for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry66, 1216–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry66, 1326–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry16, 189–194 (2004).
   PubMedGoogle Scholar
• Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J. Child Adolesc. Psychopharmacol.15, 696–702 (2005).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gendron A, McIntyre A. Quetiapine reduces residual depressive and prominent anxiety symptoms in partial responders to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) with major depression: an 8-week, double-blind, randomized, placebo-controlled study. Presented at the 14th European Congress of Psychiatry. 4th–8th March, Nice, France (2006).
   Google Scholar
• Thase ME, Rush AJ. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry63, 95–103 (2002).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Controlled Clin. Trials25, 119–142 (2004).
   PubMedGoogle Scholar
• Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med.354, 1243–1252 (2006).
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Commonwealth of Australia, Canberra, Australia (1999).
   Google Scholar
• Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry61(Suppl. 6), 4–6 (2000).
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry66(Suppl. 8), 30–40 (2005).
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother. Psychosom.75, 139–153 (2006).
   PubMed Web of Science ®Google Scholar
• Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J. Clin. Psychiatry66, 1392–1400 (2005).
   PubMed Web of Science ®Google Scholar